Is alveolar fluid clearance faster in women with acute lung injury compared to men?
These findings may have significant implications for future ALI studies and potential therapies.
Our data show that YM155 is a promising anticancer agent for ATC and that its target, survivin, is overexpressed in ATC. Our findings support the use of YM155 in clinical trials as a therapeutic option in advanced and metastatic ATC.